Zosano Pharma (NASDAQ:ZSAN) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.01, Fidelity Earnings reports.
ZSAN stock traded down $0.13 during trading on Thursday, reaching $2.79. The stock had a trading volume of 8,796 shares, compared to its average volume of 201,254. The firm has a market capitalization of $52.10 million, a P/E ratio of -0.74 and a beta of 2.60. The company has a fifty day moving average of $3.07. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.79 and a quick ratio of 0.79. Zosano Pharma has a 1-year low of $1.85 and a 1-year high of $6.65.
Several analysts have recently issued reports on the company. Maxim Group assumed coverage on Zosano Pharma in a research note on Wednesday, April 17th. They issued a “buy” rating and a $8.00 price objective on the stock. Cantor Fitzgerald assumed coverage on Zosano Pharma in a report on Monday, April 22nd. They set an “overweight” rating and a $3.66 price objective on the stock. ValuEngine raised Zosano Pharma from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research raised Zosano Pharma from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a report on Thursday, June 27th. Five research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $8.54.
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.
Featured Article: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.